ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.34−0.07 (-4.96%)
Close on Nov 13, 2026Market cap $171.08MP/E –Yield –
ADC Therapeutics cash
Cash and short-term investments held at the end of each period.
ADC Therapeutics's cash was $189.20M at Sep 30, 2026. For fiscal 2025 it was $261.34M, up 4.2% from the year before. The highest annual figure on record is $466.54M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.34M | +4.2% |
| FY2024 | Dec 31, 2024 | $250.87M | -10.0% |
| FY2023 | Dec 31, 2023 | $278.60M | -14.7% |
| FY2022 | Dec 31, 2022 | $326.44M | -30.0% |
| FY2021 | Dec 31, 2021 | $466.54M | +6.2% |
| FY2020 | Dec 31, 2020 | $439.20M | +280.1% |
| FY2019 | Dec 31, 2019 | $115.55M | -16.8% |
| FY2018 | Dec 31, 2018 | $138.81M | -47.2% |
| FY2017 | Dec 31, 2017 | $262.75M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $189.20M | -19.4% |
| Q2 FY2026 | Jun 30, 2026 | $219.11M | -17.2% |
| Q1 FY2026 | Mar 31, 2026 | $231.01M | +18.6% |
| Q4 FY2025 | Dec 31, 2025 | $261.34M | +4.2% |
| Q3 FY2025 | Sep 30, 2025 | $234.74M | -14.4% |
| Q2 FY2025 | Jun 30, 2025 | $264.56M | -11.8% |
| Q1 FY2025 | Mar 31, 2025 | $194.70M | -16.9% |
| Q4 FY2024 | Dec 31, 2024 | $250.87M | -10.0% |
| Q3 FY2024 | Sep 30, 2024 | $274.27M | -11.6% |
| Q2 FY2024 | Jun 30, 2024 | $300.12M | -13.6% |
| Q1 FY2024 | Mar 31, 2024 | $234.29M | -24.6% |
| Q4 FY2023 | Dec 31, 2023 | $278.60M | -14.7% |
| Q3 FY2023 | Sep 30, 2023 | $310.41M | -18.5% |
| Q2 FY2023 | Jun 30, 2023 | $347.51M | -7.8% |
| Q1 FY2023 | Mar 31, 2023 | $310.55M | -27.9% |
| Q4 FY2022 | Dec 31, 2022 | $326.44M | -30.0% |
| Q3 FY2022 | Sep 30, 2022 | $380.86M | -28.2% |
| Q2 FY2022 | Jun 30, 2022 | $376.78M | +1.3% |
| Q1 FY2022 | Mar 31, 2022 | $430.87M | +12.5% |
| Q4 FY2021 | Dec 31, 2021 | $466.54M | +6.2% |
| Q3 FY2021 | Sep 30, 2021 | $530.19M | +7.2% |
| Q2 FY2021 | Jun 30, 2021 | $371.88M | +6.7% |
| Q1 FY2021 | Mar 31, 2021 | $383.12M | +364.0% |
| Q4 FY2020 | Dec 31, 2020 | $439.20M | +280.1% |
| Q3 FY2020 | Sep 30, 2020 | $494.42M | +256.2% |
| Q2 FY2020 | Jun 30, 2020 | $348.59M | +32.7% |
| Q1 FY2020 | Mar 31, 2020 | $82.58M | – |
| Q4 FY2019 | Dec 31, 2019 | $115.55M | – |
| Q4 FY2018 | Dec 31, 2018 | $138.81M | – |
| Q4 FY2017 | Dec 31, 2017 | $262.75M | – |
See a number that looks wrong?